Leveraging the Synergy Between Anti-angiogenic Therapy and Immune Checkpoint Inhibitors to Treat Digestive System Cancers

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Dec 18

PMID 39691707

Authors

Qinlan Xu

Dong Shao

Affiliations

Soon will be listed here.

Abstract

The response rates to immunotherapy vary widely depending on the type of cancer and the specific treatment used and can be disappointingly low for many solid tumors. Fortunately, due to their complementary mechanisms of action, immunotherapy and anti-angiogenic therapy have synergistic effects in cancer treatment. By normalizing the tumor vasculature, anti-angiogenic therapy can improve blood flow and oxygenation to facilitate better immune cell infiltration into the tumor and enhance the effectiveness of immunotherapy. It also reduces immunosuppressive factors and enhances immune activation, to create a more favorable environment for immune cells to attack the tumor. Their combination leverages the strengths of both therapies to enhance anti-tumor effects and improve patient outcomes. This review discusses the vasculature-immunity crosstalk in the tumor microenvironment and summarizes the latest advances in combining anti-angiogenic therapy and immune checkpoint inhibitors to treat digestive system tumors.

References

Fukumura D, Kloepper J, Amoozgar Z, Duda D, Jain R . Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018; 15(5):325-340. PMC: 5921900. DOI: 10.1038/nrclinonc.2018.29. View

Chen Y, Song Y, Du W, Gong L, Chang H, Zou Z . Tumor-associated macrophages: an accomplice in solid tumor progression. J Biomed Sci. 2019; 26(1):78. PMC: 6800990. DOI: 10.1186/s12929-019-0568-z. View

Andonegui-Elguera M, Alfaro-Mora Y, Caceres-Gutierrez R, Caro-Sanchez C, Herrera L, Diaz-Chavez J . An Overview of Vasculogenic Mimicry in Breast Cancer. Front Oncol. 2020; 10:220. PMC: 7056883. DOI: 10.3389/fonc.2020.00220. View

Du S, Zhang Y, Xu J . Current progress in cancer treatment by targeting FGFR signaling. Cancer Biol Med. 2023; 20(7). PMC: 10466438. DOI: 10.20892/j.issn.2095-3941.2023.0137. View

Villalba M, Evans S, Vidal-Vanaclocha F, Calvo A . Role of TGF-β in metastatic colon cancer: it is finally time for targeted therapy. Cell Tissue Res. 2017; 370(1):29-39. DOI: 10.1007/s00441-017-2633-9. View

Protopsaltis N, Liang W, Nudleman E, Ferrara N . Interleukin-22 promotes tumor angiogenesis. Angiogenesis. 2018; 22(2):311-323. DOI: 10.1007/s10456-018-9658-x. View

Xu J, Shen J, Gu S, Zhang Y, Wu L, Wu J . Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial. Clin Cancer Res. 2020; 27(4):1003-1011. DOI: 10.1158/1078-0432.CCR-20-2571. View

Apte R, Chen D, Ferrara N . VEGF in Signaling and Disease: Beyond Discovery and Development. Cell. 2019; 176(6):1248-1264. PMC: 6410740. DOI: 10.1016/j.cell.2019.01.021. View

Kang Y, Li H, Liu Y, Li Z . Regulation of VEGF-A expression and VEGF-A-targeted therapy in malignant tumors. J Cancer Res Clin Oncol. 2024; 150(5):221. PMC: 11061008. DOI: 10.1007/s00432-024-05714-5. View

10.

Trinchieri G . Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003; 3(2):133-46. DOI: 10.1038/nri1001. View

11.

Bang Y, Golan T, Dahan L, Fu S, Moreno V, Park K . Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ). Eur J Cancer. 2020; 137:272-284. DOI: 10.1016/j.ejca.2020.06.007. View

12.

Adyns L, Proost P, Struyf S . Role of Defensins in Tumor Biology. Int J Mol Sci. 2023; 24(6). PMC: 10049535. DOI: 10.3390/ijms24065268. View

13.

Kloepper J, Riedemann L, Amoozgar Z, Seano G, Susek K, Yu V . Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proc Natl Acad Sci U S A. 2016; 113(16):4476-81. PMC: 4843473. DOI: 10.1073/pnas.1525360113. View

14.

Zhao W, Wang H, Zhang X, Zhang L, Pu W, Ma Y . Effects of IFN-γ on the immunological microenvironment and TAM polarity in stage IA non-small cell lung cancer and its mechanisms. BMC Pulm Med. 2024; 24(1):46. PMC: 10802021. DOI: 10.1186/s12890-023-02809-6. View

15.

Hao Y, Baker D, Ten Dijke P . TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis. Int J Mol Sci. 2019; 20(11). PMC: 6600375. DOI: 10.3390/ijms20112767. View

16.

Bergerot P, Lamb P, Wang E, Pal S . Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence. Mol Cancer Ther. 2019; 18(12):2185-2193. DOI: 10.1158/1535-7163.MCT-18-1399. View

17.

Mazzieri R, Pucci F, Moi D, Zonari E, Ranghetti A, Berti A . Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell. 2011; 19(4):512-26. DOI: 10.1016/j.ccr.2011.02.005. View

18.

Piqueras B, Connolly J, Freitas H, Palucka A, Banchereau J . Upon viral exposure, myeloid and plasmacytoid dendritic cells produce 3 waves of distinct chemokines to recruit immune effectors. Blood. 2005; 107(7):2613-8. PMC: 1895384. DOI: 10.1182/blood-2005-07-2965. View

19.

Cytryn S, Moy R, Cowzer D, Shah R, Chou J, Joshi S . First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial. Lancet Oncol. 2023; 24(10):1073-1082. PMC: 11208000. DOI: 10.1016/S1470-2045(23)00358-3. View

20.

Perez-Gutierrez L, Ferrara N . Biology and therapeutic targeting of vascular endothelial growth factor A. Nat Rev Mol Cell Biol. 2023; 24(11):816-834. DOI: 10.1038/s41580-023-00631-w. View